Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000912282-09-000336
Filing Date
2009-03-06
Accepted
2009-03-06 17:22:32
Documents
9
Period of Report
2008-12-31

Document Format Files

Seq Description Document Type Size
1 oncolytics20f_12312008.htm 20-F 2117119
2 GRAPHIC cryimg2.jpg GRAPHIC 2342
3 GRAPHIC img1.jpg GRAPHIC 16971
4 EMPLOYMENT AGREEMENT WITH DR. KARL METTINGER ex4_15.htm EX-4.15 99239
5 EMPLOYMENT AGREEMENT WITH MARY ANN DILLAHUNTY ex4_16.htm EX-4.16 109011
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER ex12_1.htm EX-12.1 11315
7 CERTIFICATION OF CHIEF FINANCIAL OFFICER ex12_2.htm EX-12.2 10554
8 CERTIFICATION OF CHIEF EXECUTIVE OFFICER ex13_1.htm EX-13.1 7680
9 CERTIFICATION OF CHIEF FINANCIAL OFFICER ex13_2.htm EX-13.2 7015
  Complete submission text file 0000912282-09-000336.txt   2390236
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 09664025
SIC: 2834 Pharmaceutical Preparations